Shandong Lukang Pharmaceutical (600789.SH)Nifedipine Extended-release Tablets (I) Passed Generic Drug Consistency Evaluation.

Shandong Lukang Pharmaceutical (600789.SH) announcement: The company's controlling subsidiary, Shandong Lukang Pharmaceutical Group Co., Ltd. ("Sate Company"), has received the "Drug Supplement Application Approval Notice" (Batch Number: 2023B04371) issued by the National Medical Products Administration regarding the consistency evaluation of generic drug quality and efficacy for its sustained-release Nitrendipine Tablets (I) ("the drug"). It is reported that sustained-release Nitrendipine Tablets (I) is a first-line choice for the treatment of primary hypertension. It belongs to the calcium channel blocker class and can block calcium ions from entering the cells through the channels on myocardial or vascular smooth muscle cell membranes. By interfering with calcium ion influx and reducing intracellular calcium levels, it can alter myocardial contractility and vascular tension, lower systemic vascular resistance, dilate blood vessels, and lower blood pressure. It is suitable for various types of hypertension and has good effectiveness in treating refractory and severe hypertension.